Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enzomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Agreement
Sumitomo Pharma America Enters into a CRADA with the National Cancer Institute
Details : The collaboration aims to evaluate DSP-5336 (enzomenib), an oral, small molecule designed to inhibit the menin and KMT2A protein interaction present in certain difficult to treat cancers.
Product Name : DSP-5336
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 14, 2025
Lead Product(s) : Enzomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Meropenem
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Marubeni Corporation
Deal Size : $301.0 million
Deal Type : Acquisition
Marubeni Acquires Sumitomo's Asia Pharma Unit in $480M Deal
Details : Through the acquisition, Marubeni will leverage the Sumitomo Asian approved products, which includes Meronem (meropenem trihydrate), indicated for Pneumonias.
Product Name : Meronem
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 02, 2025
Lead Product(s) : Meropenem
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Marubeni Corporation
Deal Size : $301.0 million
Deal Type : Acquisition
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Pharma America Announces U.S. FDA Approval Of GEMTESA® for OAB Symptoms
Details : Gemtesa(vibegron) is a beta-3 adrenergic receptor agonist, which is indicated for the treatment of male overactive bladder who are receiving pharmacological therapy for benign prostatic hyperplasia.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2024
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Launches ORGOVYX® in Canada for Prostate Cancer Treatment
Details : Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in Canada for testosterone suppression in patients with advanced prostate cancer.
Product Name : Orgovyx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enzomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Pharma’s DSP-5336 Receives FDA Fast Track for Acute Myeloid Leukemia
Details : DSP-5336, an Investigational menin and mixed-lineage leukemia inhibitor, is being evaluated in patients with relapsed or refractory acute myeloid leukemia with a KMT2A rearrangement.
Product Name : DSP-5336
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2024
Lead Product(s) : Enzomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Poxel
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo And Poxel Announce TWYMEEG® Study Results For Type 2 Diabetes Treatment
Details : TWYMEEG (imeglimin hydrochloride), enhances insulin action by inhibiting hepatic glucose output and improving insulin signalling in both liver and skeletal muscle, in type 2 diabetes patients.
Product Name : Twymeeg
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2024
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Poxel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : fH1,DSP-0546LP
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institutes of Biomedical Innovation, Health and nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo and Japan National Institute's universal influenza vaccine enters clinical trials
Details : fH1/DSP-0546LP is a vaccine candidate, specifically activates TLR7, being investigated for influenza.
Product Name : fH1
Product Type : Vaccine
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : fH1,DSP-0546LP
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institutes of Biomedical Innovation, Health and nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Pharma’s Vibegron Supplemental NDA Accepted By FDA
Details : Gemtesa (vibegron) is a beta-3 adrenergic receptor agonist for treating male overactive bladder (OAB) with benign prostatic hyperplasia.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Pharma Announces Authorization in Canada of Orgovyx for Treatment Prostate Cancer
Details : ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.
Product Name : Orgovyx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2023
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.
Product Name : Orgovyx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2023
Lead Product(s) : Relugolix
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable